Duloxetine replaces escitalopram once painful diabetic neuropathy joins a composite supervisor's depression, and the MN663 Unit 7 case study adds hepatic, renal and blood pressure checks to match. Searches like "mn 663 unit 7 assignment example", "mn663 unit 7 sample" and "mn663 unit 7 example" land here.
What a finished MN663 Unit 7 comorbidity case study looks like
Case summary, original plan, revision and monitoring, across about five pages. The summary gives the new facts in brackets: A1c [8.2] percent, eGFR [74], blood pressure [134/84], alcohol [two drinks a week], PHQ-9 down from [18] to [13]. The original plan is reproduced in five lines so the revision can be read against it. Three options are then weighed: keep escitalopram and add pregabalin, switch to duloxetine, or add amitriptyline. The American Diabetes Association's 2017 position statement on diabetic neuropathy (Pop-Busui et al.) is cited for duloxetine and pregabalin as initial choices for neuropathic pain. Duloxetine is chosen because it carries FDA indications for both major depression and diabetic peripheral neuropathic pain, spares him a second sedating drug, and offers a change of mechanism after a partial response. A table of revised monitoring closes the paper.
How a MN663 Unit 7 example is structured
What changed organizes the paper, not the two diagnoses taken separately. After the summary, a before-and-after layout sets the original plan beside the revised one, row by row, so every alteration is visible and carries its reason. The options section treats amitriptyline fairly, crediting its evidence in neuropathic pain, then rejects it for anticholinergic burden and cardiac conduction concerns. Pregabalin is rejected more narrowly: a second agent adds sedation and dizziness for a man who operates heavy equipment. The switch is described as [a cross-taper over a composite interval], its specifics bracketed. Coordination gets its own paragraph, with the endocrinologist informed and glucose watched because duloxetine has been associated with small rises in fasting glucose. Liver, kidney and pressure thresholds complete the revision, each tied to a label caution.
The plan as it stood
Five lines reproduce the original depression plan: agent, rationale, monitoring, follow-up and therapy referral. Seeing it whole lets a reader judge which parts the neuropathy actually disturbs and which carry forward untouched.
Three options on one page
Adding pregabalin, switching to duloxetine and adding amitriptyline are weighed against the same criteria: effect on both conditions, sedation, interaction burden and fit with his job. Using one set of criteria keeps the comparison honest.
One drug, two indications
Duloxetine's labeling covers major depression and diabetic neuropathic pain. Strong as that reason is, it is not treated as sufficient: the next lines list what the drug demands that escitalopram did not.
Heavy equipment in the reasoning
His work running a grader and roller makes sedation a safety issue, not a comfort issue. That single fact narrows the options more than any efficacy difference, and the paper says so directly.
Monitoring that grew
Liver enzymes, given the label's caution about substantial alcohol use and chronic liver disease, kidney function, blood pressure, sodium and glucose join the table. Each new row names the reason it did not exist in the first plan.
Where marks go in MN663 Unit 7
For this paper to score well, the second condition has to change the plan. The weakest version adds neuropathy to the problem list, prescribes something for it separately, and never asks how the two treatments interact, which misses the point of the unit. Graders reward a paper that tests a single agent against both diagnoses, yet they penalize one that assumes a dual indication settles everything, since duloxetine brings hepatic, renal and pressure considerations the first plan never needed. An option rejected without a reason loses credit, amitriptyline above all, given its evidence base. Coordination with the diabetes team is expected rather than optional. Beyond those, points drop for a switch described with exact amounts outside brackets, for an A1c reported without comment, and for monitoring copied unchanged from the original plan.
Get a MN663 Unit 7 example written to your instructions
Is the second condition named in your MN663 Unit 7 prompt, or is the writer asked to introduce one? Include the case, any earlier plan and the rubric. Original and revised plans side by side, each change reasoned and monitoring rebuilt for the new combination: that is what the free first case study delivers within 24-48h.
MN663 Unit 7 questions, answered
Should the paper keep the first medication if it partly worked?
Sometimes, and the paper should consider it openly. A partial response can argue for continuing and adding, or for switching to something that covers both conditions. What matters is that the choice is argued from the case: the size of the response, the new condition's demands and the burden of two drugs against one.
How much should the paper say about the medical condition itself?
Enough to show how it changes psychiatric management, and little more. For diabetic neuropathy that means its symptoms, its effect on sleep and mood, and the treatments that overlap with depression care. A full account of glycemic management belongs to another clinician, and the paper should name that clinician rather than attempt their plan.
Is it appropriate to recommend involving another specialist?
Yes, and graders usually expect it when a second condition belongs to another service. State who is contacted, what they are told and what the psychiatric plan needs from them, such as glucose results. A plan that treats a medical condition in isolation from the clinicians managing it reads as incomplete, however sound its pharmacology.